{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:52:11Z","timestamp":1782172331370,"version":"3.54.5"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Within the last decade, methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a frequent cause of purulent skin and soft tissue infections. New therapeutic options are being investigated for these infections.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We report an integrated analysis of 2 randomized, controlled studies involving omadacycline, a novel aminomethylcycline, and linezolid for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Omadacycline in Acute Skin and Skin Structure Infections Study 1 (OASIS-1) initiated patients on intravenous omadacycline or linezolid, with the option to transition to an oral formulation after day 3. OASIS-2 was an oral-only study of omadacycline versus linezolid.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 691 patients received omadacycline and 689 patients received linezolid. Infection types included wound infection in 46.8% of patients, cellulitis\/erysipelas in 30.5%, and major abscess in 22.7%. Pathogens were identified in 73.2% of patients. S. aureus was detected in 74.7% and MRSA in 32.4% of patients in whom a pathogen was identified. Omadacycline was noninferior to linezolid using the Food and Drug Administration primary endpoint of early clinical response (86.2% vs 83.9%; difference 2.3, 95% confidence interval \u20131.5 to 6.2) and using the European Medicines Agency primary endpoint of investigator-assessed clinical response at the posttreatment evaluation. Clinical responses were similar across different infection types and infections caused by different pathogens. Treatment-emergent adverse events, mostly described as mild or moderate, were reported by 51.1% of patients receiving omadacycline and 41.2% of those receiving linezolid.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Omadacycline was effective and safe in ABSSSI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT02378480 and NCT02877927.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciz396","type":"journal-article","created":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T19:13:24Z","timestamp":1557774804000},"page":"S23-S32","source":"Crossref","is-referenced-by-count":41,"title":["Omadacycline for Acute Bacterial Skin and Skin Structure Infections"],"prefix":"10.1093","volume":"69","author":[{"given":"Fredrick M","family":"Abrahamian","sequence":"first","affiliation":[{"name":"Department of Emergency Medicine, Olive View\u2013UCLA Medical Center, Sylmar"},{"name":"David Geffen School of Medicine at University of California Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Sakoulas","sequence":"additional","affiliation":[{"name":"Division of Host-Microbe Systems and Therapeutics, Center for Immunity, Infection and Inflammation, University of California San Diego School of Medicine, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Tzanis","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Manley","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Steenbergen","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita F","family":"Das","sequence":"additional","affiliation":[{"name":"AD Stats Consulting, Guerneville, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul B","family":"Eckburg","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C","family":"McGovern","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,8,1]]},"reference":[{"key":"2019080101102900800_CIT0001","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/1471-2334-13-252","article-title":"Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a US population: a retrospective population-based study","volume":"13","author":"Ray","year":"2013","journal-title":"BMC Infect Dis"},{"key":"2019080101102900800_CIT0002","first-page":"143","article-title":"Management of acute bacterial skin and skin structure infections with a focus on patients at high risk of treatment failure","volume":"4","author":"Pulido-Cejudo","year":"2017","journal-title":"Ther Adv Infect Dis"},{"key":"2019080101102900800_CIT0003","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1128\/JCM.05817-11","article-title":"Epidemiology and outcomes of complicated skin and soft tissue infections in hospitalized patients","volume":"50","author":"Zervos","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2019080101102900800_CIT0004","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1155\/1990\/649417","article-title":"Diagnosis of cellulitis in the immunocompromised host","volume":"1","author":"Carey","year":"1990","journal-title":"Can J Infect Dis"},{"key":"2019080101102900800_CIT0005","first-page":"1","article-title":"Group B streptococcus infection and diabetes: a review","volume":"4","author":"Yanai","year":"2012","journal-title":"J Microbiol Antimicrob"},{"key":"2019080101102900800_CIT0006","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/cid\/ciu444","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2019080101102900800_CIT0007","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1128\/AAC.00579-09","article-title":"Classification of staphylococcal cassette chromosome mec (SCCmec): guidelines for reporting novel SCCmec elements","volume":"53","author":"International Working Group on the Classification of Staphylococcal Cassette Chromosome Elements","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2019080101102900800_CIT0008","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0891-5520(05)70392-5","article-title":"Antimicrobial resistance in staphylococci. Epidemiology, molecular mechanisms, and clinical relevance","volume":"11","author":"Maranan","year":"1997","journal-title":"Infect Dis Clin North Am"},{"key":"2019080101102900800_CIT0009","doi-asserted-by":"crossref","first-page":"e52722","DOI":"10.1371\/journal.pone.0052722","article-title":"Epidemics of community-associated methicillin-resistant Staphylococcus aureus in the United States: a meta-analysis","volume":"8","author":"Dukic","year":"2013","journal-title":"PLOS One"},{"key":"2019080101102900800_CIT0010","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jama.2012.7139","article-title":"Epidemiology of Staphylococcus aureus blood and skin and soft tissue infections in the US military health system, 2005\u20132010","volume":"308","author":"Landrum","year":"2012","journal-title":"JAMA"},{"key":"2019080101102900800_CIT0011","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/INF.0000000000001753","article-title":"Analysis of invasive community-acquired methicillin-susceptible Staphylococcus aureus infections during a period of declining community acquired methicillin-resistant Staphylococcus aureus infections at a large children\u2019s hospital","volume":"37","author":"Hult\u00e9n","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"2019080101102900800_CIT0012","volume-title":"Guidance for industry: acute bacterial skin and skin structure infections: developing drugs for treatment","author":"Center for Drug Evaluation and Research","year":"2013"},{"key":"2019080101102900800_CIT0013","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s11739-016-1450-6","article-title":"Acute bacterial skin and skin structure infections in internal medicine wards: old and new drugs","volume":"11","author":"Falcone","year":"2016","journal-title":"Intern Emerg Med"},{"key":"2019080101102900800_CIT0014","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for community-acquired bacterial pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N Engl J Med"},{"key":"2019080101102900800_CIT0015","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1016\/j.bmc.2016.07.029","article-title":"Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic","volume":"24","author":"Tanaka","year":"2016","journal-title":"Bioorg Med Chem"},{"key":"2019080101102900800_CIT0016","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.01242-13","article-title":"In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline","volume":"58","author":"Macone","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2019080101102900800_CIT0017","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1056\/NEJMoa1800170","article-title":"Omadacycline for acute bacterial skin and skin-structure infections","volume":"380","author":"O\u2019Riordan","year":"2019","journal-title":"N Engl J Med"},{"key":"2019080101102900800_CIT0018","unstructured":"O\u2019Riordan\n              W\n            , CardenasC, SirbuA, et al\n          A Phase 3 randomized, double-blind, multi-centre study to compare the safety and efficacy of oral omadacycline to oral linezolid for treating adult subjects with ABSSSI (OASIS-2 study). In: Program and abstracts of the 28th European Congress of Clinical Microbiology and Infectious Diseases (Madrid, Spain). 2018. Presentation O0425."},{"key":"2019080101102900800_CIT0019","volume-title":"Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections [","author":"European Medicines Agency","year":"2013"},{"key":"2019080101102900800_CIT0020","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"key":"2019080101102900800_CIT0021","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4161\/viru.27135","article-title":"Systemic inflammatory response syndrome (SIRS): where did it come from and is it still relevant today?","volume":"5","author":"Balk","year":"2014","journal-title":"Virulence"},{"key":"2019080101102900800_CIT0022","first-page":"6","article-title":"The side effects of the most commonly used group of antibiotics in periodontal treatments","volume":"6","author":"Heta","year":"2018","journal-title":"Med Sci"},{"key":"2019080101102900800_CIT0023","doi-asserted-by":"crossref","first-page":"e02327-17","DOI":"10.1128\/AAC.02327-17","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe as part of the 2016 SENTRY antimicrobial surveillance program","volume":"62","author":"Pfaller","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019080101102900800_CIT0024","doi-asserted-by":"crossref","first-page":"e00047-18","DOI":"10.1128\/AAC.00047-18","article-title":"In vitro activities of omadacycline and comparators against anaerobic bacteria","volume":"62","author":"Stapert","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019080101102900800_CIT0025","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/21548331.2015.1076325","article-title":"Hospital admission patterns in adult patients with skin and soft tissue infections: identification of potentially avoidable hospital admissions through a retrospective database analysis","volume":"43","author":"Lodise","year":"2015","journal-title":"Hosp Pract (1995)"},{"key":"2019080101102900800_CIT0026","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1080\/17512433.2016.1195683","article-title":"Transitions of care in the management of acute bacterial skin and skin structure infections: a paradigm shift","volume":"9","author":"Verastegui","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2019080101102900800_CIT0027","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jemermed.2014.12.001","article-title":"Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital","volume":"48","author":"Pollack","year":"2015","journal-title":"J Emerg Med"},{"key":"2019080101102900800_CIT0028","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2334-14-296","article-title":"Incidence and cost of hospitalizations associated with Staphylococcus aureus skin and soft tissue infections in the United States from 2001 through 2009","volume":"14","author":"Suaya","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2019080101102900800_CIT0029","first-page":"449","article-title":"Potential cost-savings with once-daily aminomethylcycline antibiotic versus vancomycin in hospitalized patients with acute bacterial skin and skin structure infections","volume":"11","author":"LaPensee","year":"2018","journal-title":"Am Health Drug Benefits"},{"key":"2019080101102900800_CIT0030","doi-asserted-by":"crossref","first-page":"e0143276","DOI":"10.1371\/journal.pone.0143276","article-title":"Rising United States hospital admissions for acute bacterial skin and skin structure infections: recent trends and economic impact","volume":"10","author":"Kaye","year":"2015","journal-title":"PLOS One"},{"key":"2019080101102900800_CIT0031","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.3201\/eid1509.081228","article-title":"Trends in US hospital admissions for skin and soft tissue infections","volume":"15","author":"Edelsberg","year":"2009","journal-title":"Emerg Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/69\/Supplement_1\/S23\/29021855\/ciz396.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T05:10:53Z","timestamp":1564636253000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/69\/Supplement_1\/S23\/5541769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":31,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2019,8,1]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz396","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8,15]]},"published":{"date-parts":[[2019,8,1]]}}}